Debt Capital Markets
Senior Secured Credit Facility
Under the terms of the agreement, NEO has acquired Clarient via:
The cash component of the purchase price was funded via:
NeoGenomics, Inc. provides specialized and comprehensive cancer genetic testing services through its network of CLIA-certified clinical laboratories. The Company's advanced testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry, digital and anatomic pathology and molecular genetic testing. NeoGenomics services the needs of pathologists, oncologists, other clinicians and hospitals throughout the United States, and also provides clinical trial support services to the Pharmaceutical industry. The company has laboratories in Nashville, TN; Aliso Viejo, Irvine, Fresno and West Sacramento, CA; Houston, TX; and Tampa and Fort Myers, FL. For additional information about NeoGenomics, visit http://www.neogenomics.com/.
Clarient Diagnostics Services, Inc.
Clarient Diagnostics Services, Inc. is a provider of comprehensive cancer diagnositc testing to hospitals, physicians and the pharmaceutical industry and was a unit of GE Healthcare’s Life Sciences business. Clarient is based in Aliso Viejo, California and Houston, Texas. Clarient has approximately 415 employees and reported 2014 revenue of approximately $127mm. For additional information about Clarient, visit http://clarient.gehealthcare.c....
This material has been prepared solely for informative purposes as of its stated date and is not a solicitation, or an offer, to buy or sell any security. It does not purport to be a complete description of the securities, markets or developments referred to in the material. Information included in the material was obtained from external sources which we consider reliable, but we have not independently verified such information and do not guarantee that it is accurate or complete. Such information is believed to be accurate on the date of issuance of the material. No subsequent publication or distribution of this material shall mean or imply that any such information or opinion remains current at any time after the stated date of the material. We do not undertake to advise you of any changes in any such information or opinion. Additional information is available upon request.